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At the moment, dementia is affecting around 47 million people worldwide, with a forecast amount of 135 million affected people in
2050. Dementia is a growing health concern worldwide with no treatment currently available, but only symptomatic medication.
Effective interventions in the prevention and management of dementia are urgently needed to contain direct and indirect costs
of this disease. Indeed, the economic impact of dementia is a vast and continually growing figure, but it is still difficult to
quantify. Due to an increase in both the disease spreading and its direct and indirect costs, national and international action
plans have to be implemented. As a virtuous example, the Italian national plan for dementia has been summarized. Faced with
an increasingly less sustainable disease impact at national and international levels, the plan suggests that it is certainly the entire
welfare model that should be rethought, strengthening the network of services and providing interventions to support affected
people and their caregivers. Alongside this synergistic approach, scientific research could play a crucial role for pharmacological
and nonpharmacological treatments capable of delaying the state of loss of self-sufficiency of the patient, with a significant
impact on social and health costs.
1. Introduction
More than 47 million people are affected worldwide by
dementia, and the majority of them are over 65 years old.
For this reason, this phenomenon is considered a growing
health concern, given the increased longevity of the world
population (especially in developed countries) combinedwith
the absence of a treatment capable of modifying the disease
[1]. This occurrence creates an urgent need for effective inter-
ventions with respect to prevention and disease management.
Priorities on the dementia phenomena are comprehen-
sion of the pathology in terms of cellular, molecular, and
genetic processes and early diagnosis through the use of cog-
nitive tests and clinical trials, but mainly the understanding
of social aspects including social programs and technology
to benefit medical care and programs to contain the costs of
the disease.
The most common forms of dementia are the vascular
and the Alzheimer variations, differentiable by measuring
specific biomarkers in biological fluids, particularly in the
cerebrospinal fluid (CSF), and by imaging these biomarkers.
Both approaches are of extreme importance in optimizing a
precise early clinical diagnosis and predicting the outcome
in particular settings [2, 3].
The chronically degenerative process inducted by demen-
tia includes a set of conditions such as functional and
behavioural alterations, dynamic progression of cognitive
disabilities, loss of self-sufficiency, and increasing depen-
dence on caregivers. In this sense, the disease starts interfer-
ing with working abilities and social interactions and ends
with more or less total dependency on others, and the dam-
age done by the disease is irreversible.
Mild cognitive impairment is considered the early
stage of any form of dementia and is characterized by a
light cognitive decrease in comparison to a previous level
of capability. This decrease poorly interferes with the nor-
mal activities of the patient during the daily life, and this
condition is mainly identified in specialized centres. This
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impairment is present in about 19% of people over 65.
The conversion rate in dementia is 46% in three years
[4]. Considering that many patients do not have a direct
diagnosis of dementia at its early stages, it can be stated
that the former data underestimates the problem. At the
same time, it cannot be ignored that there are also rates
of reversion to normal cognition varying from 29 to 55%
in population-based cohort studies and from 4 to 15% in
clinical settings [5].
The two screening tools currently used for diagnosis are
the General Practitioner Assessment of Cognition (GPCog)
and the clock-drawing test, both used to screen cognitive
impairment and dementia and asmeasures of spatial dysfunc-
tion and neglect. The GPCog consists of a four-component
patient assessment and a brief informant interview (six ques-
tions) [6], whereas in the clock-drawing test, the subject is
simply asked to draw a clock from memory [7]. Besides these
two principal methods to screen dementia, there are several
other tools including the Montreal Cognitive Assessment,
the Mini-Mental State Examination, and memory- and exec-
utive function-specific measures [8, 9].
Patients with signs of cognitive decline could then be
referred to specialized structures, to undergo deeper
investigation.
In reversible forms of dementia, whose prevalence is
highly variable (8-40%, with an approximate general value
of 12% in patients presenting themselves at services with
symptoms) depending on the clinical evaluation and the
sociodemographic features of patients [10], the deficits are
secondary and, if timely and appropriately cared for, the
deterioration can regress and the patient returns to their
standard level of capability [2].
Irreversible dementias can be distinguished into a pri-
mary and a secondary form. In the primary form, the disease
is degenerative and includes Alzheimer’s disease, frontotem-
poral dementia, and dementia with Lewy bodies. In second-
ary dementia, the vascular variation is predominant [2].
At initial and intermediate stages, symptomatic charac-
teristics of all forms of irreversible dementia are quite distin-
guishable from each other; this difference in fact decreases
and disappears completely with the progress of the degener-
ation [2].
“Major neurocognitive disorders” are the current formal
identification of dementia, according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM) 5 [11], charac-
terizing them as illnesses where the neural substrate anomaly
is demonstrable, together with a cognitive deficiency, in
patients with previous normal brain capability [12].
More specifically, in 2011, the National Institute on
Aging and the Alzheimer’s Association (NIA/AA) in the
United States published new diagnostic guidelines for Alzhei-
mer’s disease focusing on three stages of the disorder: demen-
tia due to Alzheimer’s disease, mild cognitive impairment
(MCI) due to Alzheimer’s disease, and preclinical (presymp-
tomatic) Alzheimer’s disease [13–15].
In dementia due to Alzheimer’s disease, impairments in
memory, thinking, and behaviour reduce the ability to auton-
omously operate in everyday life. In mild cognitive impair-
ment due to Alzheimer’s disease, mild changes in memory
and thinking are noticeable and measurable with mental sta-
tus tests but are not severe enough to disrupt a person’s day-
to-day life. Differently, preclinical Alzheimer’s disease is a
newly defined stage of the disease where measureable bio-
marker changes in the brain may occur years before symp-
toms affecting memory, thinking, or behaviour can be
detected. In all these three stages, additional research is advo-
cated to explore if biomarkers exist to detect each of the
stages and “which biomarkers may best confirm that
Alzheimer’s-related changes are underway and how best to
measure them” [13–15].
1.1. Epidemiology. Dementia hits an increasingly high num-
ber of people: in 2015, about 47 million people were affected
and in 2050, 135 million patients are expected, with a preva-
lence of about 8% people over 65 years old in industrialized
countries, rising to more than 20% in eight years. Due to
these numbers, the World Health Organization (WHO)
and Alzheimer’s Disease International (ADI) have defined
dementia as a world health priority [1].
According to the World Alzheimer Report [1], in 2015,
the world regional distribution of new dementia cases was
4.9 million (49% of the total) in Asia, 2.5 million (25%) in
Europe, 1.7 million (18%) in the Americas, and 0.8 million
(8%) in Africa. Compared to the previous 2012 estimates,
these values represent an increased proportion of new cases
arising in Asia, the Americas, and Africa, while the propor-
tion arising in Europe has dropped [12].
The evolution of dementia epidemiology is nonhomoge-
neous: according to international studies [16–18], countries
like Sweden, Canada, the UK, the Netherlands, and the
USA experienced a decrease in dementia prevalence or inci-
dence, with a stable situation in Nigeria [19] and an increase
in incidence in China [20] and in prevalence in Japan [21].
Despite the general increase in the absolute population, two
recent studies showed a decrease in prevalence for age-
specific segments [18, 22].
Over the next 20 years, an important increase in cases
of dementia is expected in China, India, and sub-Saharan
Africa [23]. Italy ranks second for the world’s oldest popu-
lation behind Japan and before Germany and Portugal:
21.4% people are over 65 and 6.4% are over 80 [1]. In the
next 20 years or so, Chile, China, Iran, and Russia are
expected to have a proportion of elderly population similar
to Japan. By 2050, most people over 60 years old—120 mil-
lion—will live in China, while 434 million will live in the
rest of the world.
1.2. Dementia in Sub-Saharan Africa and Other Developing
Countries: Increasing Evidence Highlighting the Current and
Future Burden. About 4 million people with dementia were
living in Africa in 2015, with over 27 million people living
in other developing countries [1].
In 1990, Nigeria started the investigation on dementia
prevalence in sub-Saharan countries, with an epidemiological
study (Ibadan-Indianapolis Dementia Project). In that con-
cern, community-based researches were indicating that the
disease (Alzheimer dementia) was uncommon. After twenty
years, sub-Saharan Africa is still poorly covered by studies
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(only nine studies identified the diseases thus far, carried in
Tanzania, Benin, Central African Republic, Nigeria, and the
Republic of Congo), but there is improving evidence of
dementia prevalence.
According to the World Alzheimer Report 2015 [1], in
this region of the world, there may be a 63% increase by
2030 in the population living with dementia, with a further
increase of 257% by 2050.
Conversely, no information is currently available con-
cerning any variation in the epidemiology of dementia in
EU countries and particularly in Italy due to recent immigra-
tion flows from Africa. Indeed, it has to be considered that
immigration from Africa is still a rising phenomenon involv-
ing very young people, so that it is not possible to predict the
disease’s prevalence in EU.
1.3. Effects of Potentially Modifiable Risk Factors on the Brain.
There is a combination of nine risk factors for dementia in
about 35% cases: education limited to the age of 12, midlife
obesity and hypertension, late-life depression, loss of hear-
ing, smoking, diabetes, poor physical activity, and social
isolation [24].
On the other hand, it has been demonstrated that the
complete elimination of the apolipoprotein E (ApoE) ε4
allele, which represents the major genetic risk, can lead to a
7% decrease in disease incidence [25].
According to the current international studies, it is
observed that several dementia manifestations can now be
managed, and even if the illness per se is not curable, the evo-
lution may be modified with proper dementia care.
The following is a list of modifiable risk factors for
dementia:
(i) Vascular brain damage, which increases the risk of
macrovascular and microvascular lesions, atrophy,
and neurodegeneration [26]
(ii) Inflammation and oxidative stress, which are associ-
ated with deposition of amyloid beta peptide [27]
(iii) Metabolic syndrome and diabetes, which are associ-
ated with pathologies like atherosclerosis or brain
infarction and glucose-mediated toxicity responsible
for microvascular abnormalities and neurodegener-
ation [28]
There is also evidence of impaired insulin receptor acti-
vation in Alzheimer’s disease [29], suggesting that it might
represent a brain state that is insulin-resistant [30].
1.4. Pharmacological Treatments in Dementias. Starting from
1998, only four of the 100 drugs tested against dementia have
been authorized for use worldwide. In few cases, they can
help manage several symptoms, but most people cannot
access them. In addition, although many dementia manifes-
tations are now manageable, the underlying illness is gener-
ally not curable, even if modifiable with good dementia
care. Currently, even if a number of studies are trying to find
effective treatment for dementias, only symptomatic treat-
ments are available in practice. Two types of drugs are mainly
accessible: The cholinesterase inhibitors—galantamine, riv-
astigmine, and above all donepezil [31]—which prevent the
acetylcholinesterase enzyme from breaking down acetylcho-
line, and the neurotransmitter that connects nerve cells and
keeps memory functioning. The other type of drug is mem-
antine, an NMDA receptor antagonist that improves mem-
ory by restoring homeostasis in the glutamatergic system.
Memantine blocks the effects of glutamate, which is released
in excessive amounts in the brain of people affected by Alz-
heimer’s disease.
Since it has been shown that Alzheimer’s disease causes
an imbalance between overproduction and inadequate clear-
ance of the amyloid beta peptide that accumulates in the
brain in plaques, drugs have been developed with the aim
of stopping this phenomenon. One of these drugs is crenezu-
mab consisting of monoclonal antibodies targeting beta-
amyloid, and the other is gantenerumab, a human IgG1 anti-
body centrally acting to disassemble and degrade amyloid
plaques [32].
In addition, a cholesterol-controlling drug, gemfibrozil,
has been found to reduce amyloid levels and brain inflamma-
tion, at least in an animal model in mice and another human-
ized IgG1 version of the mouse monoclonal antibody
mAb158, and BAN2401 has been found to reduce the amy-
loid beta peptide in the brain of 81% patients and slow cogni-
tive decline in the brain by 30% [33].
In Italy, the only approved drugs to treat Alzheimer
dementia are memantine and reversible acetylcholinesterase
inhibitors: donepezil, rivastigmine, and galantamine.
These treatments are all regulated and prescribed by the
Italian Drug Agency (AIFA) in charge of drug regulation
and prescription [34]. To treat typical and atypical behav-
ioural disorders in dementia, AIFA recommends the use of
antipsychotic drugs.
1.5. Nonpharmacological Treatments. For the prevention of
dementia or as support for other treatments, nonpharmaco-
logical treatments are crucial. There are two classes of pre-
vention strategies: lifestyle-associated and diet-associated
interventions.
1.5.1. Lifestyle Strategies. Lifestyle strategies include caloric
restriction, cognitive stimulation, socialization, and physical
activity [35].
According to several studies [36, 37], physical activity
is associated with the reduction of Alzheimer dementia
prevalence [38]. Physical activity is associated with an
improvement of hippocampal neurogenesis [38] and learn-
ing capability, as demonstrated in rodents [39].
Two explanations of the neuroprotective effect of physi-
cal activity were proposed:
(1) Release of various neurotrophic factors (e.g., BDNF,
IGF-1, NGF, and VEGF), stimulating the transcrip-
tion factor (CREB) and activating the neurogenesis
and the synaptic neuronal plasticity [39]
(2) Reduction of free radicals in the hippocampus and a
concurrent increase in superoxide dismutase and
nitric oxide endothelial synthase [40]
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Although there are studies showing that mental stimula-
tion could protect against Alzheimer’s disease and cognitive
decline, they are more debatable [41]. There is evidence
showing that cognitive stimulation can induce an increase
in neuronal density [42].
1.5.2. Food Supplements and Dementias. In recent years,
many studies were aimed at confirming the preventive effect
of food supplements, such as vitamins B6 and B12, folate, and
vitamins E, C, and D [43].
Researches on vitamin B have achieved inconsistent find-
ings. For example, a two-year treatment in 271 patients with
vitamins B12 and B6 and homocysteine showed a significant
difference in cerebral atrophy indexes, compared to placebo
[44], while other reports indicate opposite results [45].
It has been shown that folic acid provides neuroprotec-
tive activity through an epigenetic mechanism, inhibiting
the accumulation of the beta-amyloid peptide [46]. Con-
versely, a three-year treatment with vitamin E did not pro-
duce any protective effect, even when adding vitamin C to
the treatment [47, 48]. Trials with vitamin D are also not
definitive [49].
Finally, an absence of reduction in Alzheimer dementia
and cognitive decline incidence after 6 years of Ginkgo
biloba treatment has been demonstrated in high-quality
trials [50–52].
2. Social Aspects of Dementia: From
Caregivers to Related Costs
There are two main social aspects of dementia: The first point
concerns the evidence that the Alzheimer’s disease preva-
lence is likely to increase [1]. A second aspect pertains to peo-
ple professionally involved in the assistance of the patients
(caregivers) and the workload and costs that this assistance
imposes to the family members [53]. For example, developed
countries face increasing health expenses, both in absolute
terms and as a percentage of the gross domestic product
[54]. Since neurological and psychiatric diseases in Europe
afflict more than 14% of the population, representing about
20% of health expenditure, this implies a segment of consid-
erable public spending [55].
2.1. Caregiver Interventions and Family Engagement in
Dementia. The term “caregiver” is used more in the United
States, Canada, and China, while “carer” or “caretaker” is
more common in the United Kingdom [56].
In any case, we can consider the following:
(i) Informal or primary caregivers, who play the role of
caring for a family member
(ii) Formal caregivers who carry out the role of assistance
(doctor, nurse, social worker, etc.)
A management strategy is required to assess the cost/-
benefit ratio of treatments, and the expansion of the number
of patients with dementia disease requires an acceleration of
efforts in these fields. This explains why international
research has developed considerably on this point. Chronic
diseases have led to financial difficulties in public health sys-
tems. Hence, the role of informal caregivers is also important
in evaluating economic and health analyses [57].
During preclinical dementia, when the disease appears
and develops until its terminal phase, the patient poses com-
plex health issues to social workers and family caregivers,
who cannot always find the correct answer from the health
and welfare services. These services, however, have not
always reached a widespread and effective organizational
model that can take into account the complexity of needs of
the elderly [57].
Indirect costs account for about 75% of total cost of
dementia, the most in the overall expenditure of the disease.
They mainly consist of a loss of productivity, on individuals,
families, and society. This very high impact is due to the loss
of autonomy of patients and to the resistance of family
members to take care of them, with consequences on health
and welfare costs [58]. To the cost of diagnosis, the cost of
home care and support for families must also be added:
shortly after the first symptoms of the disease, a patient with
Alzheimer dementia will need intensive assistance, even for
24 hours a day.
A percentage over 80% Alzheimer’s patients is assisted at
home, but during the evolution of the disease, two-thirds of
the patients incur very serious behavioural problems that
lead to stress issues for family caregivers, as well as causing
an increase in the demand for professional care, with propor-
tional greater economic commitment [57, 58].
Family members usually provide assistance to patients
with dementia: professional support is required in the most
serious cases. From the point of view of state balance, care
provided by family members is considered to be free of
charge. The assistance provided by the caregiver, on the other
hand, is a real consumption of resources and a social cost.
Consequently, a link can be established between the informal
cost of assisting the patient and the social cost of the illness.
In addition to the costs mentioned above, there are also
intangible costs, i.e., the impact due to the physical and
psychological suffering of the patient and relevant family
members, which have social and human importance. Only
towards the end of the last century, social policies and ser-
vices have identified caring as a theme to pay attention to.
Patients living in caring structures usually have a
lesser quality of life than those at home. Nevertheless,
along the evolution of dementia, it may happen that the
informal caregiver starts lacking the strength to assist
the patient. Therefore, in this situation, a possible solution
is the institutionalization by a private structure or the
identification of a professional figure who will assist the
patient at home [57, 58].
The advances in the technology of healthcare devices,
including electronic health records, portal technologies, and
wireless communications [59, 60], will probably have a key
role in future dementia care. For example, tools for remote
surveillance are very important and they give an important
contribution to improving and making safer the environ-
ment in which patients and families live [59, 60].
There are also a few European experiences about neigh-
bourhoods inhabited by patients and caregivers.
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The city of Hogewey (Netherlands) [61] has been a
European example of this since 1993, while in Rome, Italy,
there is the Alzheimer’s Village of the Fondazione Roma, in
the Bufalotta district [62], where 100 patients are hosted free
of charge in 14 houses, gathered around a square, and con-
nected to everyday services, including a bar and aminimarket.
Also in the Lombardy region, there have been active
interventions of this type, such as “Paese Ritrovato”
(retrieved village) [63], launched a few months ago by the
Cooperativa La Meridiana of Monza. It includes an area of
14,000 square meters, where 64 patients are housed, living
in 8 apartments, with single rooms, assisted bathrooms, liv-
ing areas, and a common kitchen; here, the hosted patients
can keep external contacts and implement forms of sociality.
The place is self-sufficient and, thanks to the presence of
shops, allows patients to move in a protected yet autono-
mous way.
Another fundamental service for people living with
dementia is represented by the role of Diagnostic Therapeu-
tic Care Pathways (DTCP). The DTCP is an organization
that covers both clinical and care aspects and is concerned
in addressing them with the required harmonization [64].
They are the bodies that support the patient and his fam-
ily in a straightforward way along the course of the disease,
helping recognize and properly interface the different parts
of the disease support system. The governance of the process
should be shared, with different roles and responsibilities,
between the general practitioner and the cognitive deteriora-
tion and dementia centres.
2.2. Costs Related to Dementia. The economic impact of
dementia is a vast and continually growing figure, but it is
still difficult to quantify [54]. The patients, their families,
and carers suffer economically and in terms of quality of life
[55]. Cost of dementia on the society is the sum of all
expenses concerning goods and services used to prevent,
diagnose, treat, and cope with the disease [65]. Per capita
costs are divided into three subcategories: direct medical
costs (e.g., drugs, medical and social services, hospital
resources, and professional caregivers), direct social care
costs (paid and professional home care and residential and
nursing home care), and costs of informal (unpaid) care.
Informal care is valued using an opportunity cost approach,
valuing hours of informal care by the average wage for each
country. In addition, indirect costs have to be taken into con-
sideration such as the loss of income by the patient and pos-
sibly by family members or careers. Among the studies that
have evaluated the costs of dementia [66, 67], some have
focused on the relationship between costs and severity of
the disease. Mean cost increases with the progress of the dis-
ease for patients in community dwellings, with variations
across countries. Generally speaking, cost estimates have
increased for all world regions, with the greatest relative
increases occurring in African and Eastern Asia regions
(largely driven by the upward revision of prevalence esti-
mates for these regions) [68]. Distribution of costs between
the three major subcategories (direct medical, social care,
and informal care) has not changed substantially. As
reported in 2010 [1], direct medical care costs are modest
and account for roughly 20% of global dementia costs, while
direct social sector costs and informal care costs each account
for roughly 40%. As the country income level increases, the
relative contribution of direct social care sector costs
increases and the relative contribution of informal care costs
decreases [69]. The relative contribution of informal care is
greatest in African regions and lowest in North America,
Western Europe, and several South American regions, while
the reverse is true for social sector costs [69].
Other studies focused on the economic impact of drug
therapies, concluding that cholinesterase inhibitors may be
cost-effective in a short-term perspective [70]. The neuropsy-
chiatric disorders and behavioural and psychological symp-
toms of dementia (BPSD) significantly contribute to the
overall costs of dementia care. Interventions targeted at
BPSD may help to reduce the staggering societal costs of this
illness [71, 72]. Finally, the functional dependency grade of
patients and comorbid medical conditions also affect the dis-
ease cost [73, 74]. With respect to direct medical care costs,
they account for about 20% global dementia costs, with a fur-
ther 80% divided among direct social sector and informal
care costs. The upward revision of dementia prevalence in
the African regions drove one of the greatest relative
increases in costs compared to the previous estimates in
2010 and showed also a greater contribution of informal care
to the costs [75].
In Italy, the direct costs of the assistance sum up to over
11 billion euros: 73% of the cost is charged to families, and
the average annual cost per patient is 70,587 euros, including
costs for the National Health Service [76].
Due to the expected increases in the number of people
with dementia in the next future [77], the cost of the
resources needed to support patients with dementia will sig-
nificantly increase. To address these concerns, many coun-
tries are actively developing action plans for dementia at a
national level. These plans are generally informed by a scien-
tific approach to determine the type of care to be provided,
where it is best to provide it, and the skill required of the per-
sonnel in charge of delivering it [78].
Nevertheless, many of the economic analyses reported
above do not take into account the likely decline in age-
specific dementia incidence that has been mentioned earlier
[18, 22]: if this is true, then some of the reported costs could
be considered overestimates.
2.3. Dementia as a Public Health Priority at the International
Level. With respect to dementia awareness, there is an
increasing involvement of international organizations, such
as the WHO, the Organisation for Economic Cooperation
and Development (OECD), and the EU.
During the 9th session of the Conference of the Member
States on the “Convention on the Rights of Persons with Dis-
abilities (CRPD)” [79], the United Nations (UN) dedicated a
slot to dementia reaffirming the importance of the recogni-
tion and respect of the rights of all persons with mental and
intellectual disabilities. Other initiatives have been deployed
in recent years to promote and support collaboration with
countries at international, regional, and national levels, in
response to dementia.
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The WHO hosted in March 2015 the first Ministerial
Conference on Global Action Against Dementia, to discuss
the global challenges posed by dementia, which brought
together ministers, researchers, experts, clinicians, and
nongovernmental organizations (NGOs) from around the
world. The goal was to pay attention to the socioeconomic
burden associated with dementias and how it could be
reduced, raising it at the top of the global public health
agenda. As a first result, there was the drafting of the
“Global Action Plan (GPA) on the Public Health Response
to Dementia 2017-2025,” which was later adopted by
WHO member states at the 70th World Health Assembly
in May 2017 [80].
The primary goal of the GPA is to improve the quality
of life of people (patients and caregivers) living with
dementia, to promote respect for their situation, and to
reduce the negative impact on communities and states.
To that effect, a series of actions were promoted in the fol-
lowing areas:
(1) Improving awareness on dementia; increasing public
knowledge, acceptance, and understanding of the ill-
ness; and adapting the societal environment to this
disease. This is considered a key point to enable peo-
ple with dementia to improve their social participa-
tion, give a contribution in the community, and
maximize their autonomy. It is expected that 100%
of countries will have one or more working public
awareness campaigns on dementia and that 50% of
countries will have one or more dementia-friendly
initiatives, to foster a more inclusive dementia society
by 2025
(2) Reducing the risk of dementia, by increasing the
capacity of health and social care professionals to
provide appropriate interventions to the population
and to educate about modifiable risk factors for
dementia. Managing them proactively can reduce
the risk of developing dementia, and its progression
can be delayed
(3) Ensuring diagnosis, treatment, and care to patients,
granting that the needs and preferences of people
with dementia can be met and their autonomy
respected. This result can be achieved through inte-
grated, appropriate, community-based health, psy-
chosocial, and long-term care and support focused
on the patient and, where appropriate, on families
and carers. It is expected that in at least half of coun-
tries, 50% of the estimated number of people with
dementia will be diagnosed by 2025
(4) Supporting family members and caregivers so that
the implementation of solutions to deliver multisec-
toral care, support, and services for caregivers will
help to meet their needs and will prevent a decline
in their physical and mental health and social well-
being. It is expected that, by 2025, 75% of countries
will provide support and training programmes for
caregivers and families of patients with dementia
(5) Working on information systems for dementias, in
order to start a systematic monitoring and evaluation
process of the usage of health and social care systems.
This action can provide the best evidence for policy
development and service delivery and can improve
the prevention, the accessibility, and the coordination
of care for patients with dementia, from risk reduc-
tion to the end of life. It is expected that, by 2025, half
of countries routinely will collect a core set of demen-
tia indicators, through their national health and
social information systems, with a period of two years
(6) Promoting research and technological innovation, in
order to increase the probability of effective progress
towards better prevention, diagnosis, treatment, and
care for patients with dementia. It is expected that,
between 2017 and 2025, the output of global research
on dementia will double
As a consequence of the adoption of the plan, the WHO
launched a “Global Dementia Observatory,” oriented to the
description and worldwide monitoring of the characteristics
of dementia and the relevant public health responses, pro-
vided by different countries. For the setup of this observatory,
Italy was invited to collaborate as a pilot country in order to
test the feasibility of data collection and provide suggestions
for the selection of key parameters and indicators.
2.4. Dementia as a Public Health Priority at the European
Union (EU) Level. In recent years, the “Joint Action on
Dementia (JA)” and the “Joint Programming Research Initia-
tive” were the main tools that the EU used to leverage and
translate into action the official documents that have been
produced by the commission and the council in the field of
dementias. The first of those initiatives, in which Italy has
actively participated, is called “ALCOVE” and sees the
majority of EU member states involved in research activities,
using a common scientific approach and sharing experiences.
ALCOVE, which stands for Alzheimer Cooperative Val-
uation in Europe, ended in 2013: in this project, Italy coordi-
nated the epidemiological section [81].
The participation of Italy in the second JA, which started
in 2016 and is expected to last 3 years, has the main objective
of translating the recommendations of ALCOVE into work-
ing implementations. The goal of the Act on Dementia Joint
Action is to promote collaborative actions among member
states, to increase the quality level of the lives of patients
and families living with dementia. It will provide a practical
pattern for policymakers developing and implementing their
national dementia plans and strategies. The JA is aimed at
providing practical and cost-effective examples of the core
elements of good dementia diagnosis, care, and support [82].
In addition, Alzheimer Europe, the organization that
brings together European associations concerned with the
disease, recently presented the assessment called “European
Dementia Monitor” [83], which covered almost all member
states of the EU (with the exception of Estonia) plus non-
EU member countries like Albania, Bosnia and Herzegovina,
Jersey, Monaco, Norway, Switzerland, Turkey, and Israel,
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which even if outside the EU territory are officially associated
with the EU. The analysis was developed on the basis of
ten different categories, which included the availability and
accessibility of care services, the reimbursement of medi-
cines, and the deployment of initiatives in favour of patients
living with dementia. The investigation showed significant
differences between the 36 participating countries with no
country scoring full points in all ten categories. Finland had
the best ranking with an overall score of 75.2%, followed
by England (72.4%), the Netherlands (71.2%), Germany
(69.4%), Scotland (68.8%), and Italy (52.9%).
Finland had the highest score in terms of availability
and accessibility of care services and, together with the
Netherlands and England, also scored best on initiatives
on inclusion and dementia-friendly community. Belgium,
England, Ireland, Scotland, and Sweden ranked first in
terms of reimbursement policies of drugs.
In these countries, in fact, all antidementia treatments are
fully reimbursed by the health service, and there is in force a
limit against the inappropriate use of antipsychotics. France,
Germany, and Spain scored highest in the category of clinical
trials, while Ireland and Norway were the first to recognize
dementia as a national research and policy priority.
England, France, Germany, Israel, the Netherlands, Scot-
land, and Slovenia were distinguished by following Alzhei-
mer Europe’s recommendations on respect for the legal
rights of patients with dementia and their families; Ireland
ranked first in terms of recognized care and work rights,
while Finland and Norway already ratified international
and European human rights conventions.
Although Italy is the most committed and active country
in European research collaborations, it only ranks halfway
through the general ranking because of a lack of availability
of and accessibility to care services, in addition to a low rec-
ognition of dementia as a public health priority [83].
2.4.1. National Dementia Plan of Italy. In October 2014, Italy
(one of the countries with the oldest people, as reported
above) approved the National Dementia Plan (NDP) that
was later presented at an international conference as part of
the initiatives of the Italian Presidency of the EU; it is recog-
nized that the plan contributed to strengthening the quality
of cooperation within the European Commission [84].
The plan was approved as an agreement between the
Unified Conference with local administrations, the govern-
ment, the regions, and the autonomous provinces redacting
the document “National Dementia Plan - Strategies for the
Promotion and Improvement of the Quality and Appropri-
ateness of Welfare Interventions in the Dementia Sector.”
This plan was aimed at promoting and improving inter-
ventions on specialist therapeutic aspects of dementia and
at supporting patients and their families throughout the care
process. Furthermore, it provided strategic indications for
the promotion and improvement of new strategies “starting
from the assumption that, as in all chronic degenerative
pathologies in which the pharmacological approach is not
decisive in modifying its natural history, it is necessary to
provide an articulated and organic set of care pathways,
according to a philosophy of integrated management of the
disease.” Since its launch, the NDP has represented the most
important national public health goal that aligns Italy with
the dementia policies carried out by other Western countries.
The awareness of the complexity of the dementia phenome-
non, with all its implications on the social fabric, requires
an extraordinary commitment by the central and regional
institutions in close collaboration with the associations of
family members and patients. This commitment has to be
directed towards the development of governance ability for
complex phenomena, an indispensable tool for facing this
social and health emergency [85].
It has been established that the implementation of the
plan has to be monitored through the “Monitoring Table of
the Implementation of the National Plan for Dementia
(NDP),” coordinated by the Ministry of Health, which is
aimed at reverting into concrete actions the objectives of
the plan itself.
The main objectives of the document are as follows:
Objective 1. The identification of interventions and mea-
sures in the field of health and social-health
policy, with the aim of increasing the aware-
ness of the general population, of people
with dementias and their families and pro-
fessionals, each for its own level of compe-
tence and involvement; prevention, early
diagnosis, treatment, and care of people
with dementia, also with attention to early-
onset forms; achieving, through research
support, improvement in caring for and
improving the quality of life of patients with
dementia and their caregivers. A further
goal is to organize and implement an epide-
miological survey, focused on planning and
improving care, for effective and efficient
management of the disease
Objective 2. The creation of an integrated network on
dementias and the deployment of integrated
management actions to promote prevention,
early diagnosis, and appropriate intersec-
tional policies, also with a view to reducing
discrimination. A further objective is to con-
verge to a common and homogeneous assis-
tance process, paying particular attention to
social inequalities and to conditions of fra-
gility and social and health vulnerability
Objective 3. The implementation of strategies and inter-
ventions to increase the quality of caring,
improving the ability of the NHS to deliver
and monitor effective services, through
actions such as rationalization of the supply
and the use of working methods based pri-
marily on the appropriateness of the pro-
vided services. Furthermore, promoting
strategies to improve the quality of care to
patients with dementia at home, in residen-
tial and semiresidential facilities, and during
the entire evolution of illness; eventually
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developing the appropriateness of the use
of drugs, technologies, and psychosocial
interventions
Objective 4. The increased awareness and reduction of
stigma, for the improved quality of life of
patients living with dementia and their
families, through correct information on
the disease and the available services; the
objective here is to facilitate the access to
them as early as possible
Objective 5. The improvement of the quality of life and
care and the promotion of a full social inte-
gration for patients with dementias, also
through strategies of personal and family
involvement
Objective 6. The promotion of any form of participation,
in particular through the involvement of
families and associations
After its emanation, the plan implementation was moni-
tored at the regional and national levels by evaluating the
activities of permanent confrontation and monitoring as
reported in Objective 1.
Besides the monitoring activity, the future objectives
reported in the NDP are aimed at the following:
(i) Identification of quality standards and measures for
monitoring plan activities
(ii) Elaboration of guidelines concerning crucial aspects
linked to the disease such as diagnosis communica-
tion, informed consent, and use of legal options
(iii) Discussion on ethical issues such as advance direc-
tives and accessibility to palliative care
(iv) Formulation of guidelines dedicated to patients
developing dementia in working age and focused
on early-onset dementias [86]
For the achievement of these goals, the NDP required the
activation of a permanent steering group on dementias in
order to monitor the transposition and implementation of
the NDP.
After the approval of the NDP, many activities were car-
ried out to monitor the state of transposition and implemen-
tation of the NDP at the regional level with the establishment
of two working groups to formulate the technical documents
“Diagnostic Therapeutic Care Pathways” and “System and
Information Flows,” and two national guidelines have been
drawn up to better achieve the objectives of the NDP [85].
As reported in the Ministry of Health’s document “Gen-
eral Directive for Administrative Activity and Management,”
approved in March 2019 [87], the monitoring of the NDP is
being carried out at the central level together with the 21 Ital-
ian regions and, in particular, after the approval of the two
above-reported technical documents during the Regional
Unified Conference in 2017; the formulation of a further doc-
ument on ethical issues will be completed.
Furthermore, the mental health working group created in
January 2019 by the Minister of Health will proceed to
(a) verify the implementation of the scientific guidelines,
including the agreements established in the State-
Regions Conference and Unified Conference as a
commitment of the National Action Plan for Mental
Health
(b) verify the appropriateness of the treatment and reha-
bilitation courses provided by the territorial health
services and by the psychiatric diagnosis and treat-
ment services
(c) explore the existence of any eventual critical issues in
the territorial health services and elaborate proposals
for their solution and for optimizing the network of
services, through their strengthening
(d) propose operational and regulatory actions to facili-
tate the implementation of the most appropriate
models of intervention for the psychosocial diagno-
sis, treatment, and rehabilitation of people with
mental illness, aimed at reducing compulsory and
voluntary mental health treatments and mechanical
and pharmacological restraints [87]
Nevertheless, several relevant issues still negatively affect
the management of the phenomenon of dementia in Italy.
In particular, there are many disparities of resources and
services across the different regions which demonstrate the
lack of national standards. The different aspects of dementia
management (i.e., diagnosis, assistance, and rehabilitation)
are still addressed in separate moments and processes in
different parts of the nation, severely limiting the possibility
of actually implementing an integrated approach to demen-
tia [86].
In addition, so far the National Dementia Plan has not
been financially supported and there are numerous activities
aimed at raising the awareness of the competent authorities
to identify funds for the implementation of the projects and
services established by the plan.
In conclusion, even in the presence of several unsolved
situations, it can be said that to date, Italy is improving the
management of the dementia problem both nationally and
in Europe, to develop and optimize new health and social
strategies for improving the quality of life of the people
affected by dementia and for greater appropriateness of care
interventions.
3. Conclusions
We aimed to review the most important social aspects of
dementia, briefly reminding the current epidemiology of
the disease, with a special attention to the situation in
developing countries and sub-Saharan Africa. We con-
cisely listed the modifiable risk factors for dementia and
the pharmacological and nonpharmacological treatments
including lifestyle strategies. Then, we focused on the care-
givers’ interventions and the costs related to dementia.
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They can be useful to allow policymakers to define their
choices according to the economic and social situations of
their countries [53]. This is of particular importance for
developing countries, where dementia prevalence is expected
to increase in the next decades, so that programs focused on
pharmacological but above all nonpharmacological treat-
ments (i.e., lifestyles) should be taken as soon as possible.
Conversely, in the US and Europe, where life expectancy is
already high, different strategies should be considered, taking
into account the cost of these interdisciplinary efforts includ-
ing, as previously reported [53], physicians, neuropsycholo-
gists, and economists.
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